Robert Bachoo, M.D., Ph.D.
Our Neuro-Oncology translational research laboratory focuses on understanding the fundamental mechanisms that drive malignant brain tumors. Our work aims to develop more effective therapies that will improve long-term survival and quality of life for brain tumor patients. Our patient-centric approach involves multidisciplinary teams of clinical and basic scientists. Investigational studies include genomic, metabolomics, biophysics, and drug discovery. Our laboratory has generated one of the largest repositories of clinically annotated patient-derived xenograft mouse models of high-grade gliomas and brain metastases in the country. Together with genetically engineered mouse glioma models they serve as basic discovery platforms to understand fundamental mechanisms that drive brain growth and identify potential therapeutic vulnerabilities. Our collaborators include investigators in the Departments of Biomedical Engineering at UT Dallas and UT Arlington, cancer biologists at MD Anderson Cancer Center, NIH, other academic medical centers, and drug development teams at pharmaceutical companies. Our laboratory is funded by NIH, CPRIT, national brain tumor advocacy groups, foundations, and private donations.
Amyn Habib, M.D.
We study mechanisms of resistance to targeted treatment in glioblastoma and other cancers. We are also investigating mechanisms that regulate invasion and proliferation in glioblastoma.Habib Lab Website
Edward Pan, M.D.
My research focuses on Phase I, II, and III experimental therapeutic trials for newly-diagnosed and recurrent glioblastomas, anaplastic gliomas and low-grade gliomas, brain metastases, neoplastic meningitis, and neuro-oncology quality of life trials. My research also includes Phase 0 studies evaluating blood-brain barrier penetration and intratumoral drug levels as well as novel experimental imaging modalities.